Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Angiodynamic Expects FY2024 Sales Of $270M-$275M, Reflects PICC And Midline Businesses Divestiture And Discontinuance Of RadioFrequency Ablation And Syntrax Businesses, Which Accounted For ~$50M Of Prior Guidance Of $320M-$325M Vs. Consensus Of $312.14M

Author: Benzinga Newsdesk | April 04, 2024 07:06am

Posted In: ANGO